Key Takeaways
- Puerto Rico is considering House Bill 1281, which narrows medical cannabis eligibility to patients with terminal medical conditions.
- The bill would remove the physician licensing requirement, allowing any doctor to recommend medical cannabis.
- Projected losses from the bill could reach $53 million annually, affecting crucial revenue sources like sales and income taxes.
- Hospital funding for programs reliant on cannabis tax revenue could drop, impacting trauma care and catastrophic illness treatment.
- The bill’s implications raise questions about patient access, healthcare funding, and the overall impact on Puerto Rico’s economy.
Puerto Rico lawmakers are weighing a bill that would dramatically narrow who qualifies for medical cannabis on the island. House Bill 1281, also known as P. de la C. 1281, would restrict eligibility to people diagnosed with certified terminal medical conditions, or debilitating conditions directly tied to a certified terminal illness. That’s a significant departure from the larger list of conditions currently covered under the territory’s medical cannabis law.
The bill would also eliminate an existing licensing requirement for physicians who recommend medical cannabis. Right now, doctors need a specific license from the Medical Cannabis Regulatory Board (Junta Reglamentadora del Cannabis Medicinal, or JRCM) to write these recommendations. Under the proposed changes, any licensed physician could recommend medical cannabis to eligible patients.
What makes this story worthwhile isn’t just the policy shift itself. It’s that Puerto Rico’s own fiscal watchdog has run the numbers on what tightening access could mean for government revenue, and the projected losses are substantial enough to ripple into hospital funding and public health programs.
What Does Puerto Rico’s Budget Office Say About the Bill’s Fiscal Impact?
OPAL, the Legislative Assembly Budget Office, published its analysis of House Bill 1281 this month. The office used a static analysis built around an upper-bound scenario: what happens if eligibility restrictions cause a 95% reduction in patients participating in the medical cannabis program.
Under that scenario, OPAL projects a maximum potential fiscal impact of approximately $53 million annually, beginning in fiscal year 2027. It’s important to understand what this number actually means. OPAL isn’t predicting that $53 million in losses will definitely happen. The office is modeling a worst-case outcome where the program’s economic and tax-generating activity effectively ends.
That matters for anyone trying to gauge how seriously to take the figure. It’s a ceiling, not a forecast.
Where Would the $53 Million in Losses Come From?
OPAL broke down the projected annual losses by revenue category:
- Sales and use taxes (IVU) from dispensary purchases: $23.8 million
- Income taxes: $15.5 million
- Licensing revenue from the Medical Cannabis Regulatory Board: $7.1 million
- Sales taxes tied to spending by program workers: $6 million
- Inventory taxes: $600,000
The dispensary sales tax hit is the single largest piece of the puzzle, accounting for nearly half of the total projected impact. Combined with income tax losses from both individuals and the businesses that make up the industry, these two categories are roughly three-quarters of the estimated damage.
How Would Hospital and Health Funding Be Affected?
Beyond direct tax revenue, OPAL’s report flags a secondary concern: programs that depend on medical cannabis revenue for their budgets.
The RÃo Piedras Medical Center trauma hospital receives a statutory share of IVU collections tied to medical cannabis sales. OPAL estimates that funding stream could shrink by approximately $2.2 million per fiscal year under the bill’s upper-bound scenario.
Similarly, a fund supporting treatment for catastrophic illnesses could see a reduction of about $3.9 million annually. Both allocations are tied directly to the health of the medical cannabis market, so when that market contracts, these downstream beneficiaries feel it too.
This is part of what makes House Bill 1281 an unusual case study. It’s not just a question of patient access versus public health policy. The funding mechanisms connect cannabis tax revenue to hospital trauma care and catastrophic illness treatment, meaning the bill’s effects could reach well beyond the people who use medical cannabis directly.
What Questions Remain Unanswered About House Bill 1281?
Several important details aren’t addressed in OPAL’s public summary, and they’re worth watching as this bill moves through committee.
First, how many of Puerto Rico’s current medical cannabis patients would actually lose eligibility under the new terminal-illness standard? OPAL’s 95% reduction figure is a modeling assumption built for an upper-bound estimate, not a count of real patients expected to be dropped from the program. The report doesn’t publish a current patient total or a breakdown of which qualifying conditions exist today, so the real-world impact on patients remains unclear.
Second, have lawmakers identified any alternative funding source for the hospital and catastrophic illness programs that would lose money if cannabis revenue drops? Nothing in the public OPAL summary suggests a backup plan has been proposed.
Third, there’s a genuinely interesting policy wrinkle buried in the bill text: it eliminates the physician-licensing requirement at the same time it restricts patient eligibility. Removing that credentialing step could, in theory, make it easier for more doctors to recommend medical cannabis to the smaller pool of qualifying patients.
Whether that change would meaningfully offset the bill’s restrictive effect on the overall market, or whether it’s simply a procedural cleanup with little economic consequence, is a question OPAL’s summary doesn’t quantify separately. It’s one of those details that sounds minor on paper but could shape how the policy plays out in practice.
As of writing this, House Bill 1281 remains in committee, with no floor vote scheduled.
Why Puerto Rico’s Medical Cannabis Debate Matters Beyond the Island
This situation offers a rare, clear-cut example of how cannabis policy decisions can hit multiple groups at once. Patients who currently rely on medical cannabis for non-terminal but still serious conditions could lose legal access entirely. Dispensaries, cultivators, and the thousands of workers employed across the supply chain face a shrinking market. And government programs that have come to depend on cannabis tax revenue, including trauma care and catastrophic illness treatment, would need to absorb the shortfall somehow.
Most cannabis policy fights play out in the abstract, with competing claims about public safety, youth access, or industry growth. House Bill 1281 is different because Puerto Rico’s own budget office has put a specific number on the table. That tends to sharpen the debate considerably.
Whether lawmakers view $53 million as an acceptable tradeoff for narrowing eligibility, or as a reason to reconsider the bill’s scope, is likely to shape how this plays out in committee over the coming months. For now, the OPAL report gives both supporters and critics of the bill a concrete figure to argue over, even if the underlying patient and funding questions remain open.
Frequently Asked Questions
House Bill 1281 is legislation under consideration in Puerto Rico that would limit medical cannabis eligibility to patients with certified terminal medical conditions, or debilitating conditions directly connected to a certified terminal illness. It would also remove the current licensing requirement for physicians who recommend medical cannabis, allowing any licensed physician to make such recommendations.
According to OPAL, Puerto Rico’s Legislative Assembly Budget Office, the bill could result in a maximum potential fiscal impact of approximately $53 million annually starting in fiscal year 2027. This figure is an upper-bound estimate assuming a 95% drop in eligible patients, not a confirmed projection.
The projected losses span several categories: $23.8 million in sales and use taxes from dispensary purchases, $15.5 million in income taxes, $7.1 million in licensing revenue from the Medical Cannabis Regulatory Board, $6 million in sales taxes tied to program workers’ spending, and $600,000 in inventory taxes.
Yes. OPAL estimates that the RÃo Piedras Medical Center trauma hospital could lose approximately $2.2 million in funding per fiscal year, while a fund that supports treatment for catastrophic illnesses could lose roughly $3.9 million annually. Both programs depend on a portion of medical cannabis tax revenue that state law allocates to them.
As of mid-October 2026, House Bill 1281 remains in committee in Puerto Rico’s Legislative Assembly. It has not reached a floor vote, and no timeline for further action has been publicly confirmed.
